Long-term effect of interferon-α combined with homoharringtonine on chronic myelogenous leukemia in chronic phase.

about

Current perspectives on the therapeutic aspects of chronic myelogenous leukemia.

P2860

Q38243861-3639B07C-0138-456B-9083-FBD4BA231648

P2860

Long-term effect of interferon-α combined with homoharringtonine on chronic myelogenous leukemia in chronic phase.

Item

http://www.wikidata.org/entity/Q45350588

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Long-term effect of interferon ...... ous leukemia in chronic phase.

@en

Long-term effect of interferon ...... ous leukemia in chronic phase.

@nl

type

Item

label

Long-term effect of interferon ...... ous leukemia in chronic phase.

@en

Long-term effect of interferon ...... ous leukemia in chronic phase.

@nl

prefLabel

Long-term effect of interferon ...... ous leukemia in chronic phase.

@en

Long-term effect of interferon ...... ous leukemia in chronic phase.

@nl

P1476

Long-term effect of interferon ...... ous leukemia in chronic phase.

@en

P2093

Banhe Ding

http://www.w3.org/2001/XMLSchema#string

Jiabing Zhu

http://www.w3.org/2001/XMLSchema#string

Yufeng Li

http://www.w3.org/2001/XMLSchema#string

P2860

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.

The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

BCR-ABL-transformed GMP as myeloid leukemic stem cells.

Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.

Interferon alpha for treatment of chronic myeloid leukemia.

Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor.

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib.

The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy.

P304

1426-1429

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2012.745521

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23270584

http://www.w3.org/2001/XMLSchema#string

Long-term effect of interferon-α combined with homoharringtonine on chronic myelogenous leukemia in chronic phase.

about

P2860

P2860

Long-term effect of interferon-α combined with homoharringtonine on chronic myelogenous leukemia in chronic phase.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698